Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Determination the levels of Bone Morphogentic Protein-2, P-Selectin, Substance P in β-Thalassemia Major in Iraqi Patients


Affiliations
1 Biology Department, College of Science, University of Babylon, Iraq
     

   Subscribe/Renew Journal


The current study aimed to assess BMP-2, P-selectin, substance-p in β-thalassemia major patients in Babylon Province (Iraq), by enrolling individual of Arab ancestry. A total of 70 beta-thalassemia major patients and 30 normal individual were enrolled Family history. All patients were blood transfusion depend with age mean (14.1±0.7years). On the other hand the selected control do not have history of family for thalassemia and doesn’t have any disease with mean age (15.6±1.2years). The result revealed significant decrease in BMP-2 in beta-thalassemia major patients, and significant increase in P-selectin, substance P in beta-thalassemia major patients.

Keywords

Beta-Thalassemia Major, BMP-2, P-Selectin, Substance-P, Ferritin.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Rund, D., and Rachmilewitz, E. β-Thalassemia. New England Journal of Medicine, 353(11); 2005: 1135-1146.

  • Olivieri, N. F., and Brittenham, G. M Iron-chelating therapy and the treatment of thalassemia. Blood, 89(3); 1997: 739-761.

  • Chen, H., Choesang, T., Li, H., Sun, S., Pham, P., Bao, W., ... and Blanc, L. Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation. Haematologica, haematol-101, 2016: 297–308.

  • Sage, A., Tintut, Y., Garfinkel, A., and Demer, L. Systems biology of vascular calcification. Trends in Cardiovascular Medicine, 19(4); 2009: 118-123.

  • Boström, K., Tsao, D., Shen, S., Wang, Y., and Demer, L. L. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. Journal of Biological Chemistry, 276(17); 2001: 14044-14052.

  • Sato, A. Y. S., Bub, G. L., and Campos, A. H. BMP-2 and-4 produced by vascular smooth muscle cells from atherosclerotic lesions induce monocyte chemotaxis through direct BMPRII activation. Atherosclerosis, 235(1); 2014: 45-55.

  • Yao, Y., Bennett, B. J., Wang, X., Rosenfeld, M. E., Giachelli, C., Lusis, A. J., and Boström, K. I. Inhibition of Bone Morphogenetic Proteins Protects Against Atherosclerosis and Vascular Calcification Novelty and Significance. Circulation Research, 107(4); 2010: 485-494.

  • Cappellini, M. D., Poggiali, E., Taher, A. T., and Musallam, K. M. Hypercoagulability in β-thalassemia: a status quo. Expert Review of Hematology.2012.

  • Ley, K. The role of selectins in inflammation and disease. Trends in Molecular Medicine, 9(6); 2003: 263-268.

  • McEver, R. P. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thrombosis and Haemostasis, 85(03); 2001: 746-756.

  • Frenette, P. S., Denis, C. V., Weiss, L., Jurk, K., Subbarao, S., Kehrel, B., and Wagner, D. D. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet–endothelial interactions in vivo. Journal of Experimental Medicine, 191(8); 2000: 1413-1422.

  • Page, N. M., Bell, N. J., Gardiner, S. M., Manyonda, I. T., Brayley, K. J., Strange, P. G., and Lowry, P. J. Characterization of the endokinins: human tachykinins with cardiovascular activity. Proceedings of the National Academy of Sciences, 100(10); 2003: 6245-6250.

  • Akkerman, J. W. N. Neurotransmittors act as platelet activators. Blood, 111(2); 2008: 476-476.

  • Maes, K., Nemeth, E., Roodman, G. D., Huston, A., Esteve, F., Freytes, C., and Vanderkerken, K. In anemia of multiple myeloma, hepcidinis induced by increased bone morphogenetic protein 2. Blood, 116(18); 2010: 3635-3644.

  • Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., and Nemeth, E. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. The Journal of Clinical Investigation, 120(12); 2010: 4466-4477.

  • Babitt, J. L., Huang, F. W., Xia, Y., Sidis, Y., Andrews, N. C., and Lin, H. Y. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. The Journal of Clinical Investigation, 117(7); 2007: 1933-1939.

  • Babitt, J. L., Huang, F. W., Wrighting, D. M., Xia, Y., Sidis, Y., Samad, T. A., and Andrews, N. C. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nature Genetics, 38(5); 2006: 531.

  • Truksa, J., Peng, H., Lee, P., and Beutler, E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proceedings of the National Academy of Sciences, 103(27); 2006: 10289-10293.

  • Ebeid, S. A., Sadek, N. A., El-Benhawy, S. A., and Mahmoud, G. N. Plasma substance P and soluble P-selectin as biomarkers of β-thalassemia induced hypercoagulability. Alexandria Journal of Medicine, 50(2); 2014: 107-111.

  • Ibrahim Z, Kamel M, Aziz A, Osman A, Salah M, and Nemenqani D. The potential role of RBCs and activated platelets in the Thalassemic hypercoagulable state. J Am Sci; 9(5); 2013: 518-524.

  • Sayed, S. Z., Ali, B. A., Ali, L. H., and Mohamed, M. H. A study of CD62P (P-selectin) in β-thalassemia. The Egyptian Journal of Haematology, 37(3); 2012: 162.

  • Vinchi, F., De Franceschi, L., Ghigo, A., Townes, T., Cimino, J., Silengo, L., and Tolosano, E. Hemopexin Therapy Improves Cardiovascular Function by Preventing Heme-Induced Endothelial Toxicity in Mouse Models of Hemolytic Diseases Clinical Perspective. Circulation, 127(12); 2013: 1317-1329.

  • Taher, A. T., Musallam, K. M., Cappellini, M. D., and Weatherall, D. J. Optimal management of β thalassaemia intermedia. British Journal of Haematology, 152(5); 2011: 512-523.

  • Ataga, K. I., Cappellini, M. D., and Rachmilewitz, E. A. β‐Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. British Journal of Haematology, 139(1); 2007: 3-13.

  • Eldor, A., and Rachmilewitz, E. A. The hypercoagulable state in thalassemia. Blood, 99(1); 2002: 36-43.

  • Hayashi, S. I., Watanabe, N., Nakazawa, K., Suzuki, J., Tsushima, K., Tamatani, T., and Isobe, M. Roles of P-selectin in inflammation, neointimal formation, and vascular remodeling in balloon-injured rat carotid arteries. Circulation, 102(14); 2000: 1710-1717.

  • Woollard, K. J., Kling, D., Kulkarni, S., Dart, A. M., Jackson, S., and Chin-Dusting, J. Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion. Circulation Research, 98(1); 2006: 149-156.

  • Yokoyama, S., Ikeda, H., Haramaki, N., Yasukawa, H., Murohara, T., and Imaizumi, T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. Journal of the American College of Cardiology, 45(8); 2005: 1280-1286.

  • Wagner, D. D., and Frenette, P. S. The vessel wall and its interactions. Blood, 111(11); 2008: 5271-5281.

  • Abdul-Fattah ME, Ghobrial AG, Sliman GT, and Abdul-Aal AR. Rhypecoagulability and endothelial activation in β-thalassemia major: possible role of nitric oxide deficiency. (2008).

  • Wu, H., Guan, C., Qin, X., Xiang, Y., Qi, M., Luo, Z., and Zhang, C. Upregulation of substance P receptor expression by calcitonin gene-related peptide, a possible cooperative action of two neuropeptides involved in airway inflammation. Pulmonary Pharmacology and Therapeutics, 20(5); 2007: 513-524.

  • O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F The role of substance P in inflammatory disease. J Cell Physiol 201; 2004: 167-180.

  • Kohara H, Tajima S, Yamamoto M, Tabata Y. Angiogenesis induced by controlled release of neuropeptide substance P. Biomaterials 31; 2010: 8617-8625.

  • Shrestha, B., Hashiguchi, T., Ito, T., Miura, N., Takenouchi, K., Oyama, Y., and Yoshinaga, N. B cell-derived vascular endothelial growth factor A promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. The Journal of Immunology, 184(9); 2010: 4819-4826.

  • Tazzyman, S., Lewis, C. E., and Murdoch, C. Neutrophils: key mediators of tumour angiogenesis. International Journal of Experimental Pathology, 90(3); 2009: 222-231.

  • Jones, S., Tucker, K. L., Sage, T., Kaiser, W. J., Barrett, N. E., Lowry, P. J.,and Gibbins, J. M. Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation. Blood, 111(2); 2008: 605-612.

  • Graham, G. J., Stevens, J. M., Page, N. M., Grant, A. D., Brain, S. D., Lowry, P. J., and Gibbins, J. M.. Tachykinins regulate the function of platelets. Blood, 104(4); 2004: 1058-1065.


Abstract Views: 250

PDF Views: 0




  • Determination the levels of Bone Morphogentic Protein-2, P-Selectin, Substance P in β-Thalassemia Major in Iraqi Patients

Abstract Views: 250  |  PDF Views: 0

Authors

Noor Ali Hussein
Biology Department, College of Science, University of Babylon, Iraq
Hussein Jassim Al-Harbi
Biology Department, College of Science, University of Babylon, Iraq

Abstract


The current study aimed to assess BMP-2, P-selectin, substance-p in β-thalassemia major patients in Babylon Province (Iraq), by enrolling individual of Arab ancestry. A total of 70 beta-thalassemia major patients and 30 normal individual were enrolled Family history. All patients were blood transfusion depend with age mean (14.1±0.7years). On the other hand the selected control do not have history of family for thalassemia and doesn’t have any disease with mean age (15.6±1.2years). The result revealed significant decrease in BMP-2 in beta-thalassemia major patients, and significant increase in P-selectin, substance P in beta-thalassemia major patients.

Keywords


Beta-Thalassemia Major, BMP-2, P-Selectin, Substance-P, Ferritin.

References